EQS-News: Marinomed Biotech AG announces progress with Tacrolimus Eyedrops for Entry into the Compounding Market
EQS-News: Marinomed Biotech AG / Key word(s): Expansion
Marinomed Biotech AG announces progress with Tacrolimus Eyedrops for Entry
into the Compounding Market
11.05.2026 / 11:09 CET/CEST
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Marinomed Biotech AG announces progress with Tacrolimus Eyedrops for
Entry into the Compounding Market
• Strategic Commercial Milestone: Marinomed has chosen its first product
for the compounding market, Tacrolimus eyedrops. First revenues from
partners are expected for Q4/2026 or beginning of 2027.
• Strong Clinical Validation: Feedback from a global network of leading
ophthalmologists across USA and Europe confirms a high medical need
for Tacrolimus to treat refractory ocular inflammation and to reduce
long-term steroid dependency.
Korneuburg, Austria, May 11^th, 2026 – Marinomed Biotech AG (VSE:MARI), a
healthcare-focused innovator committed to improving patient outcomes, (the
„Company“), today announced that Tacrolimus eyedrops are the prime
candidate for entering the compounding business based on input from
ophthalmologists worldwide. Marinomed expects first revenues in Q4 2026 or
beginning of 2027 from partners and fast growth in 2027. Marinomed has
gathered extensive feedback from key opinion leaders worldwide in the
field of inflammatory ocular surface disease. The experts confirmed
significant unmet medical need for Tacrolimus eyedrops in specific
indications and for certain patient populations that cannot be adequately
addressed by existing therapies. Compounded Tacrolimus eyedrops based on
the Marinosolv technology could close this gap and is also an interesting
commercial opportunity.
Strategic Entry into the Compounding Market Marinomed’s entry into the
compounding market represents a key commercial milestone in the Company’s
strategy to monetize its proprietary Marinosolv® platform. By focusing on
specialized compounding, Marinomed can address niche patient populations
and high-need therapeutic areas more rapidly than through traditional drug
development pathways. This strategy allows for faster market access and
provides a flexible commercial model to deliver innovative treatments to
patients who have exhausted standard-of-care options. In addition, the
availability of Marinosolv-based Tacrolimus eyedrops as a compounded
version is expected to support the development of Tacrosolv as licensed
pharmaceutical product in the future.
Ophthalmologists Confirm Significant Therapeutic Gap To support the
development of Tacrosolv Marinomed has established a network of renowned
specialists in the field of inflammatory eye diseases from leading
Universities in the USA, Germany, France, Italy, Spain and Austria:
All experts confirmed that Tacrolimus eyedrops address a critical medical
need for patients who do not respond to existing marketed products or
suffer from intolerable local side effects. Furthermore, the availability
of tolerable Tacrolimus formulation was cited as a beneficial way to
reduce the long-term use of steroids.
Superiority of the Marinosolv® Formulation
Currently, clinicians must rely on suboptimal alternatives, including the
off-label use of dermatological creams, which can cause significant ocular
irritation, imported products from Asia, or oil-based compounded
formulations that are often poorly tolerated by patients.
Marinomed’s solution, based on the Marinosolv® technology, offers a clear
aqueous eyedrop. Notably, this formulation remains highly effective at a
10-fold lower concentration than existing creams or imported products.
Broad Application Potential While individual specialists identified
different primary uses, the collective feedback highlighted a vast range
of potential indications, particular those currently not addressed by
existing drugs and niche indications:
• Ocular Graft-versus-host disease (GvHD)
• Persistent iritis and Mooren´s ulcer
• Mucous membrane pemphigoid and Thygeson´s keratitis
• Corneal transplant rejection and autoimmune corneal or scleral melts
In addition, physicians also would consider the use of Tacrolimus eyedrops
for patients that are refractory to corticosteroids or other
immunosuppressants in case of
• Vernal, seasonal, and atopic keratoconjunctivitis or
• Severe Dry Eye Disease (including Sjögren’s syndrome)
„Our strategy to enter the compounding market is a logical evolution for
Marinomed, allowing us to leverage our Marinosolv® technology and to
generate revenues from Q4/2026 onwards,“ said Andreas Grassauer, CEO at
Marinomed. „The feedback from these world-class institutions confirms that
our aqueous Tacrolimus formulation is not just a preference, but a
necessity for patients suffering from chronic, painful ocular
inflammations. This approach bridges the gap between innovative technology
and immediate clinical application.“
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline. The Company develops innovative
patent-protected products based on the Marinosolv® platform. The
Marinosolv® technology improves the solubility and bioavailability of
hardly soluble compounds and is used to develop new therapeutics for
autoreactive immune disorders. The Company is headquartered in Korneuburg,
Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
further information, please visit: [1] https://www.marinomed.com.
For further inquiries contact:
Marinomed Biotech AG
PR: Luca Horinek
IR.: Tobias Meister
T: +43 2262 90300 158
E-Mail: [2]pr@marinomed.com
E-Mail: [3]ir@marinomed.com
Disclaimer
The new shares and subscription rights have not been and will not be
registered under foreign securities laws – in particular under the U.S.
Securities Act of 1933, as amended („Securities Act“) – with foreign
securities authorities and may not be offered or sold, in particular in
the United States of America („US“), without registration or an exemption
from the registration requirements under the Securities Act. This
communication is not intended for distribution to or within the US and may
not be distributed or forwarded to publications with general circulation
in the US. This communication constitutes neither an offer to sell nor an
invitation to subscribe for or purchase securities in any jurisdiction in
which such an offer or such an invitation would be unlawful.
══════════════════════════════════════════════════════════════════════════
11.05.2026 CET/CEST This Corporate News was distributed by [4]EQS Group
View original content: [5]EQS News
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt, Munich,
Stuttgart, Tradegate BSX; Vienna Stock Exchange (Official
Market)
EQS News ID: 2325054
End of News EQS News Service
2325054 11.05.2026 CET/CEST
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2325054&application_name=news&site_id=apa_ots_austria~~
References
~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
2. pr@marinomed.com
3. ir@marinomed.com
4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f5d50dc7e8798b6eb177f7955e598e60&application_id=2325054&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
5. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=0ebcbe9bc727bb5c15b923d02d0d5459&application_id=2325054&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender